COCP - Cocrystal Pharma GAAP EPS of -$0.04 in-line

Cocrystal Pharma press release (NASDAQ:COCP): Q1 GAAP EPS of -$0.04 in-line. “Among our goals this year is to complete the CC-42344 Phase 1 influenza study and to initiate two Phase 1 COVID-19 studies with CDI-45205 and a novel, broad-spectrum orally administered protease inhibitor designed and developed using our proprietary structure-based drug discovery platform technology,” said James Martin, CFO and co-interim CEO. “We are well positioned to execute on these goals in the current challenging economic environment, given our clean capital structure and a cash balance we believe is sufficient to fund planned operations through 2023.”

For further details see:

Cocrystal Pharma GAAP EPS of -$0.04 in-line